- Home
- FFNW vs CLYM Comparison
FFNW vs CLYM Comparison
Compare FFNW & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFNW
- CLYM
- Stock Information
- Founded
- FFNW 1923
- CLYM 2018
- Country
- FFNW United States
- CLYM United States
- Employees
- FFNW N/A
- CLYM N/A
- Industry
- FFNW Banks
- CLYM
- Sector
- FFNW Finance
- CLYM
- Exchange
- FFNW Nasdaq
- CLYM NYSE
- Market Cap
- FFNW 203.8M
- CLYM 201.7M
- IPO Year
- FFNW N/A
- CLYM 2021
- Fundamental
- Price
- FFNW $21.30
- CLYM $1.95
- Analyst Decision
- FFNW Hold
- CLYM
- Analyst Count
- FFNW 3
- CLYM 0
- Target Price
- FFNW $23.00
- CLYM N/A
- AVG Volume (30 Days)
- FFNW 32.1K
- CLYM 264.1K
- Earning Date
- FFNW 01-23-2025
- CLYM 11-12-2024
- Dividend Yield
- FFNW 1.22%
- CLYM N/A
- EPS Growth
- FFNW N/A
- CLYM N/A
- EPS
- FFNW 0.12
- CLYM N/A
- Revenue
- FFNW $37,168,000.00
- CLYM N/A
- Revenue This Year
- FFNW N/A
- CLYM N/A
- Revenue Next Year
- FFNW $2.64
- CLYM N/A
- P/E Ratio
- FFNW $183.94
- CLYM N/A
- Revenue Growth
- FFNW N/A
- CLYM N/A
- 52 Week Low
- FFNW $13.16
- CLYM $1.86
- 52 Week High
- FFNW $23.50
- CLYM $11.55
- Technical
- Relative Strength Index (RSI)
- FFNW 27.22
- CLYM N/A
- Support Level
- FFNW $21.18
- CLYM N/A
- Resistance Level
- FFNW $22.18
- CLYM N/A
- Average True Range (ATR)
- FFNW 0.35
- CLYM 0.00
- MACD
- FFNW -0.12
- CLYM 0.00
- Stochastic Oscillator
- FFNW 10.32
- CLYM 0.00
About FFNW First Financial Northwest Inc.
First Financial Northwest Inc is the holding company. The Bank's business consists predominantly of attracting deposits from the general public, combined with borrowing from the FHLB of Des Moines and raising funds in the wholesale market then utilizing these funds to originate one-to-four family residential, multifamily, commercial real estate, construction/land, business, and consumer loans. The Bank's strategic initiatives seek to diversify its loan portfolio and broaden growth opportunities with its current risk tolerance levels and asset/liability objectives.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.